



NATF – DIRECTORS, OFFICERS, ADVISORS, VOLUNTEERS

Updated – February 1, 2008

Contents:

1. Board of Directors and Officers.....	2-3
2. Scientific Advisory Committee.....	3-4
3. International Scientific Advisory Committee.....	4-5
4. Patient Advocate/Volunteers.....	5

Contacts:

Kim Mahoney
Executive Director and Secretary
North American Thrombosis Forum (NATF)
1620 Tremont Street, Suite 3022
Roxbury Crossing, MA 02120
Phone: (617) 525-8326
Fax: (617) 738-7652
Email: kmahoney@NATFonline.org
URL: www.NATFonline.org

BOARD OF DIRECTORS & OFFICERS

Samuel Z. Goldhaber, MD - President, NATF
sgoldhaber@partners.org

Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, is a Senior Staff Member of the Cardiovascular Medicine Division of Brigham and Women's Hospital. He is Director of the Brigham and Women's Hospital (BWH) Venous Thromboembolism Research Group and Director of the Anticoagulation Service. Dr. Goldhaber is Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of venous thromboembolism.

Dr. Goldhaber co-directs four Harvard Medical School Continuing Medical Education courses: 1) a 1-day course that focuses on prevention of thrombosis (February 15, 2007), 2) a 5-day course reviewing all aspects of cardiovascular medicine (May 20-24, 2007), 3) a 1-day Thrombosis Summit (September 29, 2007), and 4) a 2-day course reviewing thrombosis and thromboembolism (October 8-9, 2008).

In May 2006, he co-chaired the 2-day Surgeon General's Workshop on DVT, which was cosponsored by the NHLBI. This Workshop will lead to the Surgeon General's planned 2007 "Call To Action" on DVT. He also serves on the National Comprehensive Cancer Network and National Quality Forum to formulate new treatment and prevention guidelines for venous thromboembolism. In November 2006, he served on a special NHLBI committee examining the pharmacogenetics of warfarin.

Jawed Fareed, PhD - Director, NATF
jfareed@lumc.edu

Jawed Fareed is Professor of Pathology and Pharmacology and Director of the Hemostasis and Thrombosis Research Laboratories at Loyola University Medical Center, Chicago, IL. Dr. Fareed's main research interest is the development of novel anticoagulant and antithrombotic drugs. He is recognized for his role in the preclinical development and initiating the first clinical trials of low-molecular-weight heparin and antithrombin agents in acute coronary syndromes. In addition, he has authored and co-authored more than 400 publications in this area.

Dr. Fareed's professional affiliations include membership on the expert panel on biologicals for the World Health Organization, and fellowships of the American Heart Association, the American College of Angiology, and the Indian College of Interventional Cardiology. He also is currently President of the South Asian Society of Atherosclerosis. Together with Professor Hans Klaus Breddin, Dr. Fareed founded the International Institute of Blood and Vascular Disorders, Frankfurt, Germany, of which he is currently the Associate Director.

Arthur A. Sasahara, MD - Director, NATF
aasahara@comcast.net

Dr. Sasahara is Senior Physician, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, and Professor of Medicine, Emeritus, Harvard Medical School, Boston, Massachusetts. Dr. Sasahara is currently Co-Director of the Venous Thromboembolism Research Group at Brigham and Women's Hospital. He obtained his M.D. from Case Western Reserve University School of Medicine and his Residency in Internal Medicine and Cardiology at Tufts, Harvard, and Yale University hospitals. He held the positions of Chief of Cardiology and Chief of Medicine at the Harvard-affiliated West Roxbury Veterans Affairs Medical Center for almost 30 years, as well as being Professor of Medicine at Harvard Medical School. In 1987, he began a 10 year leave of absence and joined Abbott Laboratories as the first Venture Head, Thrombolysis Research. In 1993, he became Senior Venture Head and in 1995, Senior Medical Consultant, Research and Development, Pharmaceutical Products Division. His major research interests are in the field of thrombolysis, hemostasis, and thrombosis. His publications include approximately 300 scientific papers and 6 books.

John Fanikos, RPh, MBA - Director and Treasurer, NATF

jfanikos@partners.org

John Fanikos, RPh, MBA, is the Assistant Director of Pharmacy at Brigham and Women's Hospital (BWH) in Boston, MA. He is also an Assistant Professor of Clinical Pharmacy Practice at both Northeastern University and the Massachusetts College of Pharmacy, where he received his B.S. in Pharmacy in 1984. He completed an American Society of Health Systems Pharmacists (ASHP) accredited residency program at BWH in 1985 and received his M.B.A. from Northeastern University in 1994. He is a member of various professional societies, among them the ASHP, the Massachusetts Society of Health System Pharmacists, and the New England Council of Hospital Pharmacists. He currently represents the New England states on the Novation Clinical Pharmacy Council. He has served in a number of difference roles at BWH ranging from investigational drug pharmacist to inpatient and outpatient pharmacy supervisor, to clinical preceptor to pharmacy administrator. Through his pharmacy practice he has worked with orthopedic, oncology, cardiology, and general medicine patients. Over the past 10 years he has worked closely with the BWH Venous Thromboembolism Service and authored/co-authored many articles on the complications of anticoagulation therapy.

Kim D. Mahoney - Executive Director and Secretary, NATF

kmahoney@NATFonline.org

Formerly Project Manager of the Venous Thromboembolism Research Group at Brigham and Women's Hospital, Cardiovascular Division, Kim Mahoney is currently the acting Executive Director of the North American Thrombosis Forum.

SCIENTIFIC ADVISORY COMMITTEE

Stephen Fredd, MD

sfreddmd@aol.com

Dr. Fredd joined the Food and Drug Administration in 1980. At FDA he held a number of leadership positions, and was the Founder and Director of the Division of Gastrointestinal and Coagulation Drug Products during his tenure. He retired from FDA in 2002, and is currently a consultant on drug development and the approval process at FDA to various interested constituencies.

Carlos Jerjes-Sanchez Diaz, MD

jerjes@prodigy.net.mx

Head, Emergency Care Department; Hospital de Enfermedades Cardiovasculares y del Torax; Association National Cardiologists of Mexico; Monterrey, Nuevo Leon, Mexico.

Kenneth Leeper, MD

ken.leeper@emoryhealthcare.org

Associate Professor of Medicine, Emory University; Director, Medical Intensive Care Unit and Respiratory Services; Section Chief, Pulmonary, Allergy, and Critical Care Medicine; Chairman, Emory Crawford Long Hospital Critical Care Committee; Emory Crawford Long Hospital; Atlanta, Georgia, USA.

Geno Merli, MD - Committee Chair, NATF

geno.merli@jefferson.edu

Professor of Medicine; Director Jefferson Center for Vascular Disease, Jefferson Medical College; Senior Vice President and Chief Medical Officer, Thomas Jefferson University Hospital; Philadelphia, Pennsylvania, USA.

Gundu Rao, PhD
raox001@unm.edu

Professor; Lillehei Heart Institute, Laboratory Medicine and Pathology; University of Minnesota; Minneapolis, Minnesota, USA.

Jeanine M. Walenga, PhD - Committee Vice Chair, NATF
jwaleng@lumc.edu

Professor, Loyola University Chicago, Stritch School of Medicine; Departments of Thoracic and Cardiovascular Surgery and Pathology; Co-Director of the Hemostasis and Thrombosis Research Laboratories; Director, Serotonin Release Assay Laboratory; Loyola University Medical Center; Maywood, Illinois, USA.

Jeffrey I. Weitz, MD
jweitz@thrombosis.hhscr.org

Professor of Medicine, McMaster University; Director, Experimental Thrombosis and Atherosclerosis Programme; Henderson Research Center; Hamilton, Ontario, Canada.

Ann K. Wittkowsky, PharmD, CACP, FASHP, FCCP
akwitt@u.washington.edu

Clinical Professor of Pharmacy; University of Washington School of Pharmacy; Director, Anticoagulation Services; University of Washington Medical Center; Seattle, Washington, USA.

INTERNATIONAL ADVISORY COMMITTEE

Henri M. Bounameaux, MD

President of the International Society on Thrombosis and Haemostasis in 2007. Division of Angiology and Hemostasis, Department of Internal Medicine, Hôpital Cantonal, University Hospitals of Geneva, Switzerland.

Benjamin Brenner, MD

Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel.

Sylvia Haas, MD

Institut für Experimentelle Onkologie, Technische Universität München, Germany.

Stavros Konstantinides, MD

Department of Cardiology and Pulmonary Medicine, Georg August University of Goettingen, Goettingen, Germany.

Ajay K. Kakkar, MD, PhD

Barts and the London, Queen Mary School of Medicine and Dentistry; Consultant Surgeon, St. Bartholomews Hospital, London; Director, Designate, Thrombosis Research Institute; Professor of Surgical Sciences; Department of Surgical Oncology and Technology; Imperial College, Hammersmith Campus, London, UK.

Vijay V. Kakkar, MD

First President, Emeritus Member, of the South Asian Society on Atherosclerosis and Thrombosis,
Director, Thrombosis Research Institute, London, UK.

NATF PATIENT ADVOCATE

Kelly Clark

kclark@NATFonline.org

Kelly Clark suffers from DVT and was hospitalized with a Pulmonary Embolism in early 2007 after knee surgery. It has now become her passion to raise awareness, educate and improve medical standards on Thrombosis.